Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional study
Purpose Bortezomib is a neurotoxic drug used in multiple myeloma and responsible for chemotherapy-induced peripheral neuropathy (CIPN). In a previous cross-sectional study, CIPN prevalence was about 26.9% in 67 patients. A second data analysis was performed to explore the relation between CIPN and auditory difficulties. Methods Based on 66 multiple myeloma patients from a single center, auditory difficulties were assessed with a self-questionnaire and compared to sensory CIPN (QLQ-CIPN20 questionnaire), patients’ characteristics and anticancer treatments. Results The prevalence of auditory difficulties was about 42.4% (95% CI [30.6–55.2]) of the 66 patients analyzed and was higher in patients with CIPN than without (82.4% vs. 28.6%, p < 0.001). Auditory difficulties were not related to the characteristics of patients and treatments. The severity of auditory difficulties were correlated to CIPN severity (spearman’s coefficient: 0.49, p = 0.009). Odds-ratio of auditory difficulties (multivariable analysis adjusted for sensory CIPN, recreation or professional noise exposure, gender, age, and treatments) was significantly associated with CIPN (18.7, 95% CI [3.0–117.1], p = 0.002). Conclusion This relation between CIPN and auditory difficulties raises concerns about hearing safety in multiple myeloma patients treated by bortezomib. Trial registration number: NCT03344328..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:279 |
|---|---|
| Enthalten in: |
European archives of oto-rhino-laryngology and head & neck - 279(2022), 4 vom: 31. Jan., Seite 2197-2201 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Giraudet, Fabrice [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Bortezomib |
|---|
| RVK: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 |
|---|
| doi: |
10.1007/s00405-021-07234-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2078276693 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2078276693 | ||
| 003 | DE-627 | ||
| 005 | 20230515194343.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00405-021-07234-1 |2 doi | |
| 035 | |a (DE-627)OLC2078276693 | ||
| 035 | |a (DE-He213)s00405-021-07234-1-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a XA 26650 |q VZ |2 rvk | ||
| 100 | 1 | |a Giraudet, Fabrice |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 | ||
| 520 | |a Purpose Bortezomib is a neurotoxic drug used in multiple myeloma and responsible for chemotherapy-induced peripheral neuropathy (CIPN). In a previous cross-sectional study, CIPN prevalence was about 26.9% in 67 patients. A second data analysis was performed to explore the relation between CIPN and auditory difficulties. Methods Based on 66 multiple myeloma patients from a single center, auditory difficulties were assessed with a self-questionnaire and compared to sensory CIPN (QLQ-CIPN20 questionnaire), patients’ characteristics and anticancer treatments. Results The prevalence of auditory difficulties was about 42.4% (95% CI [30.6–55.2]) of the 66 patients analyzed and was higher in patients with CIPN than without (82.4% vs. 28.6%, p < 0.001). Auditory difficulties were not related to the characteristics of patients and treatments. The severity of auditory difficulties were correlated to CIPN severity (spearman’s coefficient: 0.49, p = 0.009). Odds-ratio of auditory difficulties (multivariable analysis adjusted for sensory CIPN, recreation or professional noise exposure, gender, age, and treatments) was significantly associated with CIPN (18.7, 95% CI [3.0–117.1], p = 0.002). Conclusion This relation between CIPN and auditory difficulties raises concerns about hearing safety in multiple myeloma patients treated by bortezomib. Trial registration number: NCT03344328. | ||
| 650 | 4 | |a Chemotherapy-induced peripheral neuropathy | |
| 650 | 4 | |a Bortezomib | |
| 650 | 4 | |a Hearing disorders | |
| 650 | 4 | |a Multiple myeloma | |
| 700 | 1 | |a Selvy, Marie |4 aut | |
| 700 | 1 | |a Kerckhove, Nicolas |4 aut | |
| 700 | 1 | |a Pereira, Bruno |4 aut | |
| 700 | 1 | |a Barreau, Fantine |4 aut | |
| 700 | 1 | |a Nguyen, Daniel |4 aut | |
| 700 | 1 | |a Busserolles, Jérôme |4 aut | |
| 700 | 1 | |a Cabrespine, Aurélie |4 aut | |
| 700 | 1 | |a Chaleteix, Carine |4 aut | |
| 700 | 1 | |a Soubrier, Martin |4 aut | |
| 700 | 1 | |a Bay, Jacques-Olivier |4 aut | |
| 700 | 1 | |a Lemal, Richard |4 aut | |
| 700 | 1 | |a Balayssac, David |0 (orcid)0000-0002-6126-6588 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European archives of oto-rhino-laryngology and head & neck |d Springer Berlin Heidelberg, 2004 |g 279(2022), 4 vom: 31. Jan., Seite 2197-2201 |w (DE-627)385027494 |w (DE-600)2141531-6 |w (DE-576)111041562 |x 0937-4477 |7 nnns |
| 773 | 1 | 8 | |g volume:279 |g year:2022 |g number:4 |g day:31 |g month:01 |g pages:2197-2201 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00405-021-07234-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4277 | ||
| 936 | r | v | |a XA 26650 |
| 951 | |a AR | ||
| 952 | |d 279 |j 2022 |e 4 |b 31 |c 01 |h 2197-2201 | ||